Cargando…

Evaluation of (18)F-fluorothymidine positron emission tomography ([(18)F]FLT-PET/CT) methodology in assessing early response to chemotherapy in patients with gastro-oesophageal cancer

BACKGROUND: 3’-Deoxy-3’-[(18)F]fluorothymidine ([(18)F]FLT) PET has limited utility in abdominal imaging due to high physiological hepatic uptake of a tracer. We evaluated [(18)F]FLT-PET/CT combined with a temporal-intensity information-based voxel-clustering approach termed kinetic spatial filterin...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, R., Mapelli, P., Hanna, G. B., Goldin, R., Power, D., Al-Nahhas, A., Merchant, S., Ramaswami, R., Challapalli, A., Barwick, T., Aboagye, E. O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5112222/
https://www.ncbi.nlm.nih.gov/pubmed/27854031
http://dx.doi.org/10.1186/s13550-016-0234-3
_version_ 1782467950992687104
author Sharma, R.
Mapelli, P.
Hanna, G. B.
Goldin, R.
Power, D.
Al-Nahhas, A.
Merchant, S.
Ramaswami, R.
Challapalli, A.
Barwick, T.
Aboagye, E. O.
author_facet Sharma, R.
Mapelli, P.
Hanna, G. B.
Goldin, R.
Power, D.
Al-Nahhas, A.
Merchant, S.
Ramaswami, R.
Challapalli, A.
Barwick, T.
Aboagye, E. O.
author_sort Sharma, R.
collection PubMed
description BACKGROUND: 3’-Deoxy-3’-[(18)F]fluorothymidine ([(18)F]FLT) PET has limited utility in abdominal imaging due to high physiological hepatic uptake of a tracer. We evaluated [(18)F]FLT-PET/CT combined with a temporal-intensity information-based voxel-clustering approach termed kinetic spatial filtering (KSF) to improve tumour visualisation in patients with locally advanced and metastatic gastro-oesophageal cancer and as a marker of early response to chemotherapy. Dynamic [(18)F]FLT-PET/CT data were collected before and 3 weeks post first cycle of chemotherapy. Changes in tumour [(18)F]FLT-PET/CT variables were determined. Response was determined on contrast-enhanced CT after three cycles of therapy using RECIST 1.1. RESULTS: Ten patients were included. Following application of the KSF, visual distinction of all oesophageal and/or gastric tumours was observed in [(18)F]FLT-PET images. Among the nine patients available for response evaluation (RECIST 1.1), three patients had responded (partial response) and six patients were non-responders (stable disease). There was a significant association between Ki-67 and all baseline [(18)F]FLT-PET parameters. Area under the curve (AUC) from 0 to 1 min was associated with treatment response. CONCLUSIONS: The results of this study indicate that application of the KSF allowed accurate visualisation of both primary and metastatic lesions following imaging with the proliferation marker, [(18)F]FLT-PET/CT. However, [(18)F]FLT-PET uptake parameters did not correlate with response. Instead, we observe significant changes in tracer delivery following chemotherapy suggesting that further [(18)F]FLT-PET/CT studies in this tumour type should be undertaken with caution.
format Online
Article
Text
id pubmed-5112222
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-51122222016-12-19 Evaluation of (18)F-fluorothymidine positron emission tomography ([(18)F]FLT-PET/CT) methodology in assessing early response to chemotherapy in patients with gastro-oesophageal cancer Sharma, R. Mapelli, P. Hanna, G. B. Goldin, R. Power, D. Al-Nahhas, A. Merchant, S. Ramaswami, R. Challapalli, A. Barwick, T. Aboagye, E. O. EJNMMI Res Original Research BACKGROUND: 3’-Deoxy-3’-[(18)F]fluorothymidine ([(18)F]FLT) PET has limited utility in abdominal imaging due to high physiological hepatic uptake of a tracer. We evaluated [(18)F]FLT-PET/CT combined with a temporal-intensity information-based voxel-clustering approach termed kinetic spatial filtering (KSF) to improve tumour visualisation in patients with locally advanced and metastatic gastro-oesophageal cancer and as a marker of early response to chemotherapy. Dynamic [(18)F]FLT-PET/CT data were collected before and 3 weeks post first cycle of chemotherapy. Changes in tumour [(18)F]FLT-PET/CT variables were determined. Response was determined on contrast-enhanced CT after three cycles of therapy using RECIST 1.1. RESULTS: Ten patients were included. Following application of the KSF, visual distinction of all oesophageal and/or gastric tumours was observed in [(18)F]FLT-PET images. Among the nine patients available for response evaluation (RECIST 1.1), three patients had responded (partial response) and six patients were non-responders (stable disease). There was a significant association between Ki-67 and all baseline [(18)F]FLT-PET parameters. Area under the curve (AUC) from 0 to 1 min was associated with treatment response. CONCLUSIONS: The results of this study indicate that application of the KSF allowed accurate visualisation of both primary and metastatic lesions following imaging with the proliferation marker, [(18)F]FLT-PET/CT. However, [(18)F]FLT-PET uptake parameters did not correlate with response. Instead, we observe significant changes in tracer delivery following chemotherapy suggesting that further [(18)F]FLT-PET/CT studies in this tumour type should be undertaken with caution. Springer Berlin Heidelberg 2016-11-16 /pmc/articles/PMC5112222/ /pubmed/27854031 http://dx.doi.org/10.1186/s13550-016-0234-3 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research
Sharma, R.
Mapelli, P.
Hanna, G. B.
Goldin, R.
Power, D.
Al-Nahhas, A.
Merchant, S.
Ramaswami, R.
Challapalli, A.
Barwick, T.
Aboagye, E. O.
Evaluation of (18)F-fluorothymidine positron emission tomography ([(18)F]FLT-PET/CT) methodology in assessing early response to chemotherapy in patients with gastro-oesophageal cancer
title Evaluation of (18)F-fluorothymidine positron emission tomography ([(18)F]FLT-PET/CT) methodology in assessing early response to chemotherapy in patients with gastro-oesophageal cancer
title_full Evaluation of (18)F-fluorothymidine positron emission tomography ([(18)F]FLT-PET/CT) methodology in assessing early response to chemotherapy in patients with gastro-oesophageal cancer
title_fullStr Evaluation of (18)F-fluorothymidine positron emission tomography ([(18)F]FLT-PET/CT) methodology in assessing early response to chemotherapy in patients with gastro-oesophageal cancer
title_full_unstemmed Evaluation of (18)F-fluorothymidine positron emission tomography ([(18)F]FLT-PET/CT) methodology in assessing early response to chemotherapy in patients with gastro-oesophageal cancer
title_short Evaluation of (18)F-fluorothymidine positron emission tomography ([(18)F]FLT-PET/CT) methodology in assessing early response to chemotherapy in patients with gastro-oesophageal cancer
title_sort evaluation of (18)f-fluorothymidine positron emission tomography ([(18)f]flt-pet/ct) methodology in assessing early response to chemotherapy in patients with gastro-oesophageal cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5112222/
https://www.ncbi.nlm.nih.gov/pubmed/27854031
http://dx.doi.org/10.1186/s13550-016-0234-3
work_keys_str_mv AT sharmar evaluationof18ffluorothymidinepositronemissiontomography18ffltpetctmethodologyinassessingearlyresponsetochemotherapyinpatientswithgastrooesophagealcancer
AT mapellip evaluationof18ffluorothymidinepositronemissiontomography18ffltpetctmethodologyinassessingearlyresponsetochemotherapyinpatientswithgastrooesophagealcancer
AT hannagb evaluationof18ffluorothymidinepositronemissiontomography18ffltpetctmethodologyinassessingearlyresponsetochemotherapyinpatientswithgastrooesophagealcancer
AT goldinr evaluationof18ffluorothymidinepositronemissiontomography18ffltpetctmethodologyinassessingearlyresponsetochemotherapyinpatientswithgastrooesophagealcancer
AT powerd evaluationof18ffluorothymidinepositronemissiontomography18ffltpetctmethodologyinassessingearlyresponsetochemotherapyinpatientswithgastrooesophagealcancer
AT alnahhasa evaluationof18ffluorothymidinepositronemissiontomography18ffltpetctmethodologyinassessingearlyresponsetochemotherapyinpatientswithgastrooesophagealcancer
AT merchants evaluationof18ffluorothymidinepositronemissiontomography18ffltpetctmethodologyinassessingearlyresponsetochemotherapyinpatientswithgastrooesophagealcancer
AT ramaswamir evaluationof18ffluorothymidinepositronemissiontomography18ffltpetctmethodologyinassessingearlyresponsetochemotherapyinpatientswithgastrooesophagealcancer
AT challapallia evaluationof18ffluorothymidinepositronemissiontomography18ffltpetctmethodologyinassessingearlyresponsetochemotherapyinpatientswithgastrooesophagealcancer
AT barwickt evaluationof18ffluorothymidinepositronemissiontomography18ffltpetctmethodologyinassessingearlyresponsetochemotherapyinpatientswithgastrooesophagealcancer
AT aboagyeeo evaluationof18ffluorothymidinepositronemissiontomography18ffltpetctmethodologyinassessingearlyresponsetochemotherapyinpatientswithgastrooesophagealcancer